Waldemar Debinski to Brain Neoplasms
This is a "connection" page, showing publications Waldemar Debinski has written about Brain Neoplasms.
Connection Strength
7.067
-
Rossmeisl JH, Herpai D, Quigley M, Cecere TE, Robertson JL, D'Agostino RB, Hinckley J, Tatter SB, Dickinson PJ, Debinski W. Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas. Neuro Oncol. 2021 03 25; 23(3):422-434.
Score: 0.495
-
Sanders S, Debinski W. Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma. Int J Mol Sci. 2020 Apr 16; 21(8).
Score: 0.464
-
Sharma P, Debinski W. Receptor-Targeted Glial Brain Tumor Therapies. Int J Mol Sci. 2018 Oct 25; 19(11).
Score: 0.419
-
Ferluga S, Tomé CM, Herpai DM, D'Agostino R, Debinski W. Simultaneous targeting of Eph receptors in glioblastoma. Oncotarget. 2016 Sep 13; 7(37):59860-59876.
Score: 0.362
-
Ferluga S, Debinski W. Ephs and Ephrins in malignant gliomas. Growth Factors. 2014 Dec; 32(6):190-201.
Score: 0.319
-
Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, Debinski W. Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. J Neurooncol. 2014 Feb; 116(3):447-54.
Score: 0.299
-
Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. PLoS One. 2013; 8(10):e77719.
Score: 0.296
-
Pandya H, Debinski W. Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy. BioDrugs. 2012 Aug 01; 26(4):235-44.
Score: 0.272
-
Pandya H, Gibo DM, Garg S, Kridel S, Debinski W. An interleukin 13 receptor a 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol. 2012 Jan; 14(1):6-18.
Score: 0.256
-
Debinski W, Gibo DM. Fos-related antigen 1 (Fra-1) pairing with and transactivation of JunB in GBM cells. . 2011 Jan 15; 11(2):254-62.
Score: 0.244
-
Debinski W, Tatter SB. Convection-enhanced delivery to achieve widespread distribution of viral vectors: Predicting clinical implementation. Curr Opin Mol Ther. 2010 Dec; 12(6):647-53.
Score: 0.242
-
Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother. 2009 Oct; 9(10):1519-27.
Score: 0.223
-
Liu TF, Cai J, Gibo DM, Debinski W. Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin. Clin Cancer Res. 2009 Jan 01; 15(1):160-8.
Score: 0.212
-
Debinski W. Drug cocktails for effective treatment of glioblastoma multiforme. Expert Rev Neurother. 2008 Apr; 8(4):515-7.
Score: 0.201
-
Wykosky J, Gibo DM, Stanton C, Debinski W. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res. 2008 Jan 01; 14(1):199-208.
Score: 0.198
-
Debinski W. Naturally occurring, unmodified bacterial toxin for the treatment of glioblastoma multiforme? . 2006 Nov; 5(11):1569-70.
Score: 0.183
-
Debinski W. Personalized, multivalent, and more affordable: the globalization of vaccines. Clin Cancer Res. 2005 Aug 15; 11(16):5663-4.
Score: 0.168
-
Debinski W, Gibo DM. Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res. 2005 Apr; 3(4):237-49.
Score: 0.164
-
Debinski W, Gibo D, Mintz A. Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors. Ann N Y Acad Sci. 2003 Mar; 983:232-42.
Score: 0.142
-
Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia. 2002 Sep-Oct; 4(5):388-99.
Score: 0.137
-
Debinski W. Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest. 2002; 20(5-6):801-9.
Score: 0.131
-
Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, Kittel CA, D'Agostino RB, Tatter SB, Laxton AW, Frenkel MB, Hawkins GA, Herpai D, Sanders S, Sarkaria JN, Lesser GJ, Debinski W, Strowd RE. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. 2020 09 16; 10(1):15195.
Score: 0.119
-
Soike MH, Logue J, Qasem S, Hughes RT, McTyre E, Su J, Triozzi P, Bendandi M, Lo HW, Ahmed T, O'Neill SS, Debinski W, Pasche B, Watabe K, Miller LD, Chan MD, Ruiz J. CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Sci Rep. 2019 10 07; 9(1):14385.
Score: 0.112
-
Sirkisoon SR, Carpenter RL, Rimkus T, Doheny D, Zhu D, Aguayo NR, Xing F, Chan M, Ruiz J, Metheny-Barlow LJ, Strowd R, Lin J, Regua AT, Arrigo A, Anguelov M, Pasche B, Debinski W, Watabe K, Lo HW. TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene. 2020 01; 39(1):64-78.
Score: 0.111
-
Soike MH, McTyre ER, Shah N, Puchalski RB, Holmes JA, Paulsson AK, Miller LD, Cramer CK, Lesser GJ, Strowd RE, Hinson WH, Mott RT, Johnson AJ, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns? Neuroradiology. 2018 Oct; 60(10):1043-1051.
Score: 0.103
-
Rimkus TK, Carpenter RL, Sirkisoon S, Zhu D, Pasche BC, Chan MD, Lesser GJ, Tatter SB, Watabe K, Debinski W, Lo HW. Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Res. 2018 05 15; 78(10):2589-2600.
Score: 0.100
-
Sattiraju A, Solingapuram Sai KK, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A. IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget. 2017 Jun 27; 8(26):42997-43007.
Score: 0.096
-
Randolph DM, McTyre ER, Paulsson AK, Holmes JA, Hinson WH, Lesser GJ, Strowd R, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma. Clin Neurol Neurosurg. 2016 Dec; 151:73-78.
Score: 0.091
-
Qian X, Tan H, Zhang J, Liu K, Yang T, Wang M, Debinskie W, Zhao W, Chan MD, Zhou X. Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study. Oncotarget. 2016 Aug 23; 7(34):55377-55394.
Score: 0.090
-
Haughton ME, Chan MD, Watabe K, Bonomi M, Debinski W, Lesser GJ, Ruiz J. Treatment of brain metastases of lung cancer in the era of precision medicine. Front Biosci (Elite Ed). 2016 Jan 01; 8:219-32.
Score: 0.086
-
Carpenter RL, Paw I, Zhu H, Sirkisoon S, Xing F, Watabe K, Debinski W, Lo HW. The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis. Oncotarget. 2015 Sep 08; 6(26):22653-65.
Score: 0.084
-
Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, Chan MD. Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget. 2015 Aug 07; 6(22):18945-55.
Score: 0.084
-
Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. J Neurooncol. 2015 Sep; 124(3):447-53.
Score: 0.083
-
Paw I, Carpenter RC, Watabe K, Debinski W, Lo HW. Mechanisms regulating glioma invasion. Cancer Lett. 2015 Jun 28; 362(1):1-7.
Score: 0.082
-
Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol. 2014 Sep; 119(2):429-35.
Score: 0.078
-
Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol. 2014 Apr; 37(2):177-81.
Score: 0.076
-
Rossmeisl JH, Garcia PA, Daniel GB, Bourland JD, Debinski W, Dervisis N, Klahn S. Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients. Vet Radiol Ultrasound. 2014 Mar-Apr; 55(2):115-32.
Score: 0.074
-
Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Ra2 tumor-restricted biomarker. Neuro Oncol. 2012 Oct; 14(10):1239-53.
Score: 0.068
-
Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, Rodriguez R, Lowenstein PR, Castro MG. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A. 2010 Nov 16; 107(46):20021-6.
Score: 0.060
-
Schwartzbaum J, Ahlbom A, Malmer B, Lönn S, Brookes AJ, Doss H, Debinski W, Henriksson R, Feychting M. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res. 2005 Jul 15; 65(14):6459-65.
Score: 0.042